TRDA Entrada Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why TRDA matters now
Entrada Therapeutics, Inc. (TRDA) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.40 with +1.09% on the session and $287.3M in market capitalization; recent performance reads 1-month +25.49% and YTD -31.03%.
The latest financial table shown here is Q1 2026, with revenue of $875.0K, net income of $-39.7M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -47.8%.
The latest indexable market news headline is "Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Zeiher Bernhardt G filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.10
P/S
47.97
EV/EBITDA
-1.51
DCF Value
$10.10
FCF Yield
-47.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-598.0%
Operating Margin
-3109.3%
Net Margin
-2895.1%
ROE
-51.2%
ROA
-49.5%
ROIC
-55.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $875.0K | $-39.7M | $-0.95 |
| Q4 2025 | $1.3M | $-39.2M | $-0.95 |
| FY 2025 | $25.4M | $-143.8M | $-3.47 |
| Q3 2025 | $1.6M | $-44.1M | $-1.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$16.00
Target (Median)
$17.00
Target Range
$10.00 - $21.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.26
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.